

**Title Page:**

**Full Title:** Mitigating the Severity of COVID-19 Illness in the Primary Care Patient Population through Early Identification and Close Monitoring of Underlying Comorbidities

**Short Title:** Early Identification of COVID-19 Severity in Primary Care Patients

Payal Parikh, MD, FACP<sup>1</sup>, Patricia Greenberg, MS,<sup>2,3</sup> Shmuel Halpert, BA<sup>4</sup>, Allison Abrishami, BA<sup>5</sup>, Liora Rabizadeh, BA<sup>5</sup>, Hannah Shayefar, BS<sup>6</sup>, Lauren Tetelbaun, BMSc<sup>7</sup>, Dovid Friedman, MD<sup>4</sup>, Jeffrey Kaminetzky, MD<sup>4</sup>

**Author Affiliations:**

1. Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
2. Biostatistics and Epidemiology Services Center, Rutgers School of Public Health, Rutgers University, Piscataway, NJ, USA.
3. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers University, Piscataway, NJ, USA.
4. Chemed Health Center, Lakewood, NJ, USA
5. Department of Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
6. Department of Cognitive Science, University of California, Los Angeles, Los Angeles, CA, USA.
7. Bachelor of Medical Sciences, Western University, London, ON, Canada

## Author Details:

**Corresponding Author:** Parikh, P. is an Assistant Professor of Medicine and Vice Chair for Patient Safety and Quality Improvement, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Contact info: 732-235-7112, fax: 732-235-7144, email: parikhpd@rwjms.rutgers.edu

Greenberg, P., MS, is the Administrative Manager and a Senior Biostatistician for the Rutgers University Biostatistics and Epidemiology Services Center within the Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers University, Piscataway, NJ, USA.

Shmuel Halpert has a BA biology. Lead data analyst CHEMED Health Center, Lakewood NJ, USA

Abrishami, A.D. has a Bachelor of Arts in Psychology from the University of California, Los Angeles, Los Angeles, CA, USA.

Liora Rabizadeh has a Bachelor of Arts in Psychology from the University of California, Los Angeles, Los Angeles, CA, USA.

Hannah Shayefar has a Bachelor of Science from the Department of Cognitive Science, University of California, Los Angeles, Los Angeles, CA, USA.

Lauren Tetelbaun has a Bachelor of Medical Sciences from the Western University, London, ON, Canada

Dovid Friedman, MD is Chief Executive Officer for CHEMED Health Center, Lakewood NJ, USA

Jeffrey Kaminetzky, MD is the Chief Medical Officer for the CHEMED Health Center, Lakewood NJ, USA

Research reported in this publication was supported by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institute of Health (NIH) under award number UL1TR003017. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The study was approved by the Institutional Review Board at Rutgers Robert Wood Johnson Medical School.

The authors report no external funding source for this study.

The authors declare no conflict of interest.

All authors listed have contributed to the collection and analysis of data as well as manuscript preparation. We have no tables or figures that have been printed elsewhere.

The authors certify that the manuscript is a unique submission and is not being considered for publication by any other source in any medium. Further, the manuscript has not been published, in part or in full, in any form.

Correspondence should be addressed to Payal D. Parikh, 125 Paterson St, CAB 2320 New Brunswick, NJ, 08901; telephone: (732) 325-7254; fax: (732) 235-7122; email: [drparikhzemse@gmail.com](mailto:drparikhzemse@gmail.com) Twitter: @Payalia320.

Word Count: 2699

Tables 4 Main Tables, 1 supplemental table

Figures: 1 supplemental figure

## Abstract

**Purpose:** Prior studies have identified risk factors which prognosticate severity of SARS-CoV-2 illness among hospitalized patients. Since the majority of patients first present to ambulatory care sites, there is a need to identify early predictors of disease progression in this population.

**Methods:** This retrospective cohort study investigated the impact of underlying comorbid conditions on SARS-CoV-2 infection severity in the ambulatory setting. All patients who presented to a single federally qualified health center (FQHC) between March-May 2020 with a positive SARS-CoV-2 test were reviewed for inclusion. Patient demographics, symptomology, prior medical history, and outcomes were collected.

**Results:** 301 patients were included, with nearly equal numbers of patients with (n=151) and without (n=150) underlying comorbidities. Overall, 269 patients (89%) had a mild outcome and 32 patients (11%) had a severe outcome. Advanced age (OR: 9.4 [95% CI: 3.4-27.4],  $p < 0.001$ ) and male gender (OR: 3.2 [95% CI: 1.2-9.8],  $p = 0.02$ ) were significant predictors of severe outcomes. Additionally, every obesity category (1: BMI = 30.0–34.9; 2: BMI = 35–39.9; 3: BMI = 40.0+) was associated with more severe outcomes compared to non-obese (OR: 3.5,  $p = 0.05$ ; OR: 5.2,  $p = 0.03$ ; OR: 13.9,  $p = 0.01$ ). Compared to an HbA1C  $< 6$ , an HbA1C of 7.1–8.0 showed a clinically significant association.

**Conclusion:** SARS-CoV-2 severity can be prognosticated in the ambulatory population by the presence and severity of pre-existing comorbidities. Early identification and risk stratification of these comorbidities will allow clinicians to develop plans for closer monitoring to prevent severe illness.

## Keywords

- [COVID-19](#)
- Ambulatory Management

- [Health services research](#)
- [Outcomes research](#)
- [SARS-CoV-2](#)
- Outpatient Medicine
- Preventative Medicine
- Comorbid Conditions

### **Abbreviations:**

ARDS – Acute Respiratory Distress Syndrome

COPD – Chronic Obstructive Pulmonary Disease

EMR – Electronic Medical Record

HbA1C – glycosylated hemoglobin

BMI – Body Mass Index

### **Introduction**

Patients infected with SARS-CoV-2 present with variable signs and symptoms, from asymptomatic to Acute Respiratory Distress Syndrome (ARDS)<sup>1</sup>. The relationship between severity of illness and nonmodifiable risk factors is well established. However, modifiable risk factors, such as underlying comorbid conditions are presently under investigation. In hospitalized patients, poor prognosis is linked with underlying comorbidities including cardiovascular disease, immunodeficiency, lung disease, and the components of the metabolic syndrome (obesity, hypertension, diabetes, and hyperlipidemia)<sup>2</sup>. In addition, patients with diabetes have increased rates of hospital and ICU admissions with increasing morbidity and mortality<sup>2,3</sup> and patients with COPD are four times more likely to contract SARS-CoV-2, with a higher likelihood of developing more severe illness compared to patients without COPD<sup>4</sup>. While disease progression has been extensively evaluated in the inpatient population, there is little evidence

predicting disease progression in primary care patients who present to the outpatient setting. As such, the ability to prognosticate the potential severity of illness and develop a plan for more frequent monitoring is necessary.

This study reports on the relationship between underlying comorbidities and disease progression on a retrospective cohort of SARS-CoV-2 positive primary care patients. The goal is to guide ambulatory physicians' focus on more frequent monitoring of these high-risk patients, thus allowing for earlier and more aggressive intervention.

## **Methods**

### ***Participants***

This retrospective cohort study utilized patient chart data from the ambulatory population presenting to the CHEMED Health Center in Lakewood, New Jersey. Records for all adult patients aged 18 or older, who received SARS-CoV-2 testing at the health center between March 1 - May 31, 2020 were reviewed for study inclusion. All SARS-CoV-2 positive patients (confirmed by PCR testing or significant levels of IgG antibodies) with underlying comorbidities - defined as any patient who had a prior or current diagnosis of diabetes, hypertension, obesity, and/or a history of previous thromboembolic event - were identified and selected for analysis. Confirmed SARS-CoV-2 positive controls (those without underlying comorbidities) were randomly selected and matched to those with comorbidities, based on the combination of three demographic characteristics: age group (1: 18-40 years old, 2: 41-64, 3: 65-80, 4: 81+), sex (female or male), and self-selected ethnicity, which was pared down to the NIH recommended racial and ethnic categories<sup>5</sup>. The randomized matching was performed using Microsoft Excel, first matching on the combination of age group and sex, and then on race as a tertiary factor. Study exclusion criteria included age below 18 and pregnancy at the time of health center visit.

### ***Study Design***

#### **Medical Record Review and Comorbidity Classification**

Retrospective chart reviews were conducted using the CHEMED EMR database for all participants in the study. Chart extraction included self-selected ethnicity, comorbid conditions, current medication list, and recent BMI calculation, blood pressure measurement, and HbA1c level, when available. The comorbidities were defined on a scale of 1-3 as follows: Diabetes by HbA1c (1: <6.4; 2: 6.5-8.9; 3: >9) based on ADA Guidelines<sup>6</sup>, Hypertension by blood pressure (1: 120-129/<80, 2: 130-139/80-89, 3: >=140/>=90) based on the JNC8 Guidelines<sup>7</sup>, the presence of anti-hypertensive medications, specifically ACE Inhibitors or Angiotensin Receptor Blockers (ARBs), and Obesity by body mass index (BMI) (1: 30-34.9, 2: 35-39.9, 3: >=40). History of prior thromboembolic events was categorized as “yes” or “no” via an absolute count. IRB approval was obtained through the primary author’s institutional requirements.

#### Procedure and Telephone Survey

As part of routine care, all patients who tested positive for SARS-CoV-2 were contacted regarding their health status using a follow-up questionnaire which included the patient’s health status post SARS-CoV-2 infection, initial presenting symptoms, and severity of illness including the need for home oxygen, and/or hospitalization (Supplemental Figure 1). Past medical history was confirmed as part of routine care. For non-English speaking patients, a translator line was used. Researchers ranked the patients’ SARS-CoV-2 infection severity on a scale from 1 to 4 using a modified version of the NIH Clinical Spectrum of SARS-CoV-2 infection tool<sup>8</sup> (1: asymptomatic; 2: mildly symptomatic; 3: symptomatic and requiring oxygen (moderate), 4: hospitalized (severe/critical)).

To align with the initial ambulatory diagnostic process, disease severity was further pared down to, mild and severe; differentiated by the need for additional therapies. Mild was defined by either asymptomatic or symptomatic presentation alone, while severe was defined by symptomatic presentation requiring supplemental oxygen or hospitalization.

#### Statistical Analysis

In order to examine balance in the charts selected for analysis, all study measures were first summarized overall and by their comorbidity group status using range, mean and standard deviation (SD), and median with interquartile range (IQR) for continuous measures, frequency with percentage for the categorical measures, and a combination of frequency with percentage and median with IQR for ordinal measures. Bivariate group comparisons were done using Pearson Chi-Square, Fisher's Exact, or Wilcoxon Rank Sum tests, where appropriate.

The primary outcome, SARS-CoV-2 severity, was explored with both bivariate and multivariate methods. In the bivariate analyses, the SARS-CoV-2 severity outcome was compared across the study measure-based groups using Kruskal-Wallis, Wilcoxon Rank Sum, Pearson Chi-Square, and Fisher's Exact tests for association, and spearman correlation testing for ordinal vs. ordinal or ordinal vs. non-normally distributed continuous measures. Multivariable Firth logistic regression models were then used to examine which combination of study measures were predictive of the 2 level ("Mild", "Severe") SARS-CoV-2 severity outcome. Patient demographics and comorbidities were used as the primary predictors for these models. Results of the models are presented as coefficient estimates and as odds ratios (OR) with 95% confidence intervals (CI).

All statistical analyses were completed using R version 4.1.1 statistical software<sup>9</sup>, including the use of the "DescTools" and "logistf" packages<sup>10,11</sup>, and any two-sided p-value < 0.05 was considered to be statistically significant.

## Results

We analyzed clinical data from a total of 301 patients diagnosed with SARS-CoV-2, with a nearly equal subset of patients with underlying comorbidities (n=151) and those without (n=150). While gender was well matched between the groups (p = 0.59), there was a significant difference in the 4-level age categorization (p = 0.01); therefore, age was instead collapsed into a 2-level categorization (1: 18-64 vs 2:



65+) as shown in Table 1, which was then balanced between the groups ( $p = 0.35$ ). The patient population was predominantly White or Caucasian race (97%), which was also well-matched among the two arms ( $p = 0.42$ ). However, when combined with Hispanic/Latino ethnicity, there was a much higher proportion of Non-Hispanic White patients in the control group compared to the comorbidity group (96.0% vs 80.8%,  $p < 0.001$ ).

As shown in Table 2, underlying health conditions in the comorbidity group ( $n=151$ ) were obesity 76.2%, hypertension 46.4%, diabetes 27.2%, asthma 7.3%, current smoker 6.0%, COPD 0.7%, and no patients were identified with having a history of thromboembolic events. The mean (SD) conditions per patient in the comorbidity arm was 1.6 (0.7) and the median (IQR) was 2 [1, 2].

Per Table 3, the majority (87.7%) of patients were symptomatic at presentation during SARS-CoV-2 infection diagnosis. In the total study population, more than 50% of the patients presented with fever, weakness and fatigue, and malaise. More patients presented with cough, shortness of breath, and cardiopulmonary symptoms in the comorbidity group while, more patients presented with weakness and fatigue in the control group. For progression of illness, the majority of patients in both the comorbidity (84.1%) and control (94.7%) groups were identified as symptomatic without the need for additional therapies. A significantly higher proportion of patients in the comorbidity group versus the control group presented with a higher severity of illness, defined as symptomatic requiring home oxygen or subsequent hospitalization (15.9% vs 5.3%,  $p = 0.003$ ), respectively.

When collapsing the severity of SARS-CoV-2 illness outcome to 2 levels: “Mild” (defined as being either asymptomatic or having symptoms, but not requiring additional therapy) versus “Severe” (defined as having symptoms and requiring at home oxygen or hospitalization), there were 269 patients who had a Mild outcome and 32 patients who had a Severe outcome. As shown in Table 4A, only advanced age (OR: 8.0 [95% CI: 3.2, 20.7],  $p < 0.001$ ), male gender (OR: 3.1 [95% CI: 1.2, 8.7],  $p = 0.02$ ), and having been diagnosed with obesity (OR: 3.7 [95% CI: 1.5, 9.5],  $p = 0.004$ ) were significant predictors of a more severe SARS-CoV-2 illness. Given the significant association identified between having obesity and a

more severe outcome, an additional penalized multivariable logistic regression model was fit (Table 4B), where more distinct categories were used for diabetes, hypertension (HTN), and obesity. Similarly, in this model, advanced age (OR: 9.4 [95% CI: 3.4, 27.4],  $p < 0.001$ ) and male gender (OR: 3.2 [95% CI: 1.2, 9.8],  $p = 0.02$ ) were still significant predictors of a more severe outcome. In addition, compared to not being diagnosed with obesity, all 3 levels of obesity (1: BMI = 30.0 – 34.9; 2: BMI = 35 – 39.9; 3: BMI = 40.0+) were significantly associated or just over the threshold for significance (OR: 3.5,  $p = 0.05$ ; OR: 5.2,  $p = 0.03$ ; OR: 13.9,  $p = 0.01$ ) for increasing the odds of a more severe outcome. While not statistically significant at the 0.05 level, compared to having an HbA1C level  $< 6$ , having an HbA1C level of 7.1 – 8.0 (OR: 15.5 [95% CI: 0.8, 244.8],  $p = 0.06$ ) showed a clinically significant association.

As shown in Supplementary Table 1, only 5.2% patients with no underlying comorbid conditions were in the severe category as compared to patients with one comorbidity; diabetes (16.7%), hypertension (11.8%), or obesity (8.9%). Additionally, when evaluating combinations of the comorbid conditions, 28.1% of patients with hypertension and obesity, followed by 14.3% of patients with diabetes and obesity and 12.5% of patients with diabetes and hypertension, had a more severe outcome. Furthermore, among patients who had all three underlying comorbid conditions ( $n = 13$ ), 30.8% had more severe illness.

### **Discussion:**

In patients presenting with SARS-CoV-2 infection, there is general consensus that non-modifiable risk factors, older age and male gender, are predictors of severe disease among hospitalized patients<sup>12</sup>. Our findings in the primary care population are consistent; older age and male gender predicted a significantly higher likelihood of severe illness (OR:9 and OR: 3 respectively,  $p < 0.05$ ). Regarding ethnicity, while underrepresented minorities have been identified with more severe outcomes,<sup>13</sup> our study did not find a statistical significance.

However, among modifiable risk factors, there is greater evidence on the inpatient population, as compared to the ambulatory primary care population, that utilizes comorbidities as predictors of severity of illness. To our knowledge, this is the first study which predicts the progression of illness in the ambulatory population based solely on underlying high risk comorbid conditions, such as those of the components of metabolic syndrome.

We identified a significant association between the number of comorbid conditions and patients with mild (asymptomatic) vs severe (requiring home oxygen or hospitalization) outcomes (Mean (SD): 0.7 (0.9) vs 1.5 (1.1),  $p < 0.01$ ). For each additional comorbidity, the odds of having a more severe outcome were 2.1 [95% CI: 1.40, 3.10] times higher. This is consistent with inpatient literature, identifying the risk of death in patients with 2-5 underlying comorbid conditions was 2.55 times that of those without<sup>14</sup>. We further evaluated the components of metabolic syndrome, specifically obesity, hypertension, and diabetes, since they have been identified as predictors of more severe illness, due to an underlying proinflammatory state, and increased expression of ACE2 receptors in lung and adipose tissue<sup>15,16,17</sup>. Our study showed that 30.8% of patients with obesity, hypertension, and diabetes together had a severe outcome as compared to 22.2% with two of the three comorbid conditions, and less than 17% with diabetes, hypertension, or obesity alone.

Notably, our findings (Table 4A) show that obesity alone had a fourfold increase on progression to severe illness, especially those with a BMI of 40+ showing a nearly 14 times higher likelihood of severe SARS-CoV-2 infection. This is consistent with Yang et al, where a higher BMI was associated with increased incidence of severe SARS-CoV-2 infection, especially as obesity is related to increased expression of ACE2 and subsequent end organ damage, and respiratory compromise leading to acute respiratory distress syndrome (ARDS) due to increased abdominal pressure limiting chest expansion<sup>18,19,20,21</sup>.

Hypertension and diabetes are among the most common underlying comorbid conditions in patients infected with SARS-CoV-2<sup>22</sup>, with a relative risk of 2.84 and 2.61 respectively<sup>23</sup>, however, to date there is no evidence of whether these are independent risk factors or additive. While our study showed that the

presence of hypertension was predictive of more severe illness, it was not a statistically significant independent risk factor ( $p = 0.21$ ). (Table 4A). Additional analysis evaluating the stages of hypertension (Table 4B) showed that patients who presented in Stage 3 exhibited a lower likelihood of having severe illness (OR [95% CI]: 0.36 [0.09, 1.29]) compared to normotensive patients. Additionally, there was no significant association with disease severity ( $p = 0.50$ ) in patient prescribed an ACEI or ARB. Our results suggest that while hypertension may play a role in cardiovascular illness, it is not an independent risk factor for acute SARS-CoV-2 related illness and requires further evaluation.

Diabetes, especially with complication, has also been implicated in severity of SARS-CoV2 illness<sup>14</sup>. In our study, hypertension and/or diabetes accounted for 73.6% of the patients, and the prevalence of diabetes alone was 16.7% in the severe category which was higher than hypertension or obesity alone (Supplemental Table 1). While diabetes in general has been well established as a higher risk factor there has been limited evaluation of the stages of diabetes control and its relationship with severe illness. Our analysis shows that patients with a baseline A1C of greater than 6.5 mg/dL (category 2-4) had an increasing likelihood of progression to severe illness. (Table 4B). The increase was only clinically significant for diabetic patients with an A1C between 7.1 - 8.0 mg/dL (category 3), who exhibited a 15.5 times higher likelihood of progression to severe disease ( $p=0.06$ ). Patients with an A1C  $> 9.0$  had the lowest odds of progression to severe illness (OR [95%CI]: 0.47 [0.00, 7.94],  $p = 0.64$ ). One possible explanation is that diabetes requires a balance of control<sup>24</sup> which requires further evaluation as the use of insulin and oral hypoglycemics was not available in our study. Since SARS-CoV-2 has the ability to destroy islets via the angiotensin-converting enzyme 2 (ACE2) receptor, and promote hyperglycemia during acute illness<sup>25</sup>, further analysis evaluating fasting blood sugar will delineate the risk of disease progression among SARS-CoV-2 patients with underlying diabetes.

Numerous studies have identified an association between acute SARS-CoV-2 infection, disease progression and presence of underlying comorbid conditions. As such, there is an increased need to closely monitor patients in the ambulatory setting, both as preventative, prior to infection, and during

acute infection with SARS-CoV2. To augment preventative measures, there is a role for primary care physicians in enrolling patients in nutrition and weight loss programs to encourage control of diabetes. Once infected there is a role for closer monitoring of the SARS-CoV-2 infected patients who have additional underlying comorbidities to prevent severe decompensation. This may include augmented monitoring of hypoxia with ambulatory pulse oximetry, improving pulmonary rehab with the use of incentive spirometers, augmented access to point of care glucose monitoring in the ambulatory setting, and increased frequency of tele visits for earlier identification of severe disease progression.

### **Limitations:**

There are several limitations due to the observational and retrospective chart review study design. First, this is a single FQHC in Lakewood, New Jersey with the majority patients identified as Caucasian. Second, there is a small sample size of 150 patients in each arm; however, they were matched by age category and gender in an attempt to help counteract these potential confounders. Third, all the data collected about underlying comorbid conditions was identified based on chart review at the time of presentation for severe illness, and additional follow up questions from the survey may have potentially been affected by patient recall bias. Due to the high volume and large scale of the pandemic, labs were not routinely checked and medication adherence for comorbid conditions was not routinely monitored.

### **Conclusion:**

The progression of SARS-CoV-2 infection can be prognosticated in the ambulatory population by the presence and severity of pre-existing comorbidities. Early identification and risk stratification of these comorbidities will allow clinicians to develop plans for closer monitoring to prevent severe illness.

### **Acknowledgments**

The authors thank Michael Steinberg, MD for contributing to the review of the manuscript from an ambulatory physician perspective and for Yaakov Schwartz, BA for facilitating access to these data. The

findings and conclusions in this report are those of the authors and the authors have no funding to disclose. No copyrighted materials were used in this article.

### **Conflict of Interest**

The authors declare no conflict of interest.

### **Author Information**

Corresponding Author: Payal Parikh, MD, FACP Rutgers, Robert Wood Johnson Medical School.

Clinical Academic Building, 125 Paterson Street, CAB 2320, New Brunswick, NJ 08901. Telephone:

732-325-7254. Email: [parikhpd@rwjms.rutgers.edu](mailto:parikhpd@rwjms.rutgers.edu). Twitter: @Payalia320

### **References**

1. Sartor Z, Hess B. Increasing the Signal-to-Noise Ratio: COVID-19 Clinical Synopsis for Outpatient Providers. *J Prim Care Community Health*. 2020;11:2150132720922957.  
doi:10.1177/2150132720922957
2. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect*. 2020;26(6):767-772.  
doi:10.1016/j.cmi.2020.04.012
3. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr*. 2020;14(4):303-310.  
doi:10.1016/j.dsx.2020.04.004
4. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. *J Med Virol*. 2020;92(10):1915-1921.  
doi:10.1002/jmv.25889

5. Racial and Ethnic Categories and Definitions for NIH Diversity Programs and for Other Reporting Purposes. National Institutes of Health. Available at <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-089.html>. Accessed [4.22.22].
6. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes-2021* [published correction appears in *Diabetes Care*. 2021 Sep;44(9):2182]. *Diabetes Care*. 2021;44(Suppl 1): S15-S33. doi:10.2337/dc21-S002
7. Armstrong C; Joint National Committee. JNC8 guidelines for the management of hypertension in adults. *Am Fam Physician*. 2014;90(7):503-504.
8. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [4.22.22]
9. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.URL: <https://www.R-project.org/>.
10. Andri Signorell et mult. al. (2021). DescTools: Tools for descriptive statistics. R package version 0.99.43.
11. Georg Heinze, Meinhard Ploner and Lena Jiricka (2020). logistf: Firth's Bias-Reduced Logistic Regression. R package version 1.24. URL:<https://CRAN.R-project.org/package=logistf>
12. Centers for Disease Control and Prevention. Provisional COVID-19 Death Counts by Sex, Age, and State.
13. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine*. 2020; 23:100404. Published 2020 Jun 3. doi:10.1016/j.eclinm.2020.100404.

14. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. *Prev Chronic Dis*. 2021;18: E66. Published 2021 Jul 1. doi:10.5888/pcd18.210123
15. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published correction appears in JAMA. 2020 May 26;323(20):2098]. *JAMA*. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
16. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? *Nutr Metab Cardiovasc Dis*. 2004;14(5):228-232. doi:10.1016/s0939-4753(04)80048-6
17. Bansal R, Gubbi S, Muniyappa R. Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. *Endocrinology*. 2020;161(10): bqa112. doi:10.1210/endo/bqa112
18. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: A systematic review and meta-analysis. *J Med Virol*. 2021;93(1):257-261. doi:10.1002/jmv.26237
19. Csige I, Ujvárosy D, Szabó Z, et al. The Impact of Obesity on the Cardiovascular System. *J Diabetes Res*. 2018; 2018:3407306. Published 2018 Nov 4. doi:10.1155/2018/3407306.
20. Malhotra A, Hillman D. Obesity and the lung: 3. Obesity, respiration and intensive care. *Thorax*. 2008;63(10):925-931. doi:10.1136/thx.2007.086835
21. Steele RM, Finucane FM, Griffin SJ, Wareham NJ, Ekelund U. Obesity is associated with altered lung function independently of physical activity and fitness. *Obesity (Silver Spring)*. 2009;17(3):578-584. doi:10.1038/oby.2008.584



22. Paudel SS. A meta-analysis of 2019 novel coronavirus patient clinical characteristics and comorbidities. Research Square. 2020. 10.21203/rs.3.rs-21831/v1 [Accessed April 18, 2020, <https://www.researchsquare.com/article/rs-21831/v1>]
23. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. *Aging Dis.* 2020;11(3):668-678. Published 2020 May 9. doi:10.14336/AD.2020.0502
24. Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metab.* 2020;31(6):1068-1077.e3. doi:10.1016/j.cmet.2020.04.021
25. Das S, K R A, Birangal SR, et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. *Life Sci.* 2020; 258:118202. doi:10.1016/j.lfs.2020.118202

**Tables:**

**Table 1: Study patient demographics overall and by group.**

<b>Study Measure</b>	<b>Total Study Sample (n = 301)</b>	<b>Group 1: Comorbidities (n = 151)</b>	<b>Group 2: Controls (n = 150)</b>	<b>P-Value</b>
<b>Age Category (4-level), n (%)</b>				<b>p = 0.01</b>
18-40 years old (1)	119 (39.5)	45 (29.8)	74 (49.3)	
41-64 years old (2)	133 (44.2)	78 (51.6)	55 (36.7)	
65-80 years old (3)	40 (13.3)	22 (14.6)	18 (12.0)	
81+ years old (4)	9 (3.0)	6 (4.0)	3 (2.0)	
<b>Age Category (2-level), n (%)</b>				<b>p = 0.35</b>
18-64 years old (1)	252 (83.7)	123 (81.5)	129 (86.0)	
65+ years old (2)	49 (16.3)	28 (18.5)	21 (14.0)	
<b>Gender, n (%)</b>				<b>p = 0.59</b>
Female	117 (38.9)	61 (40.4)	56 (37.3)	
Male	184 (61.1)	90 (59.6)	94 (62.7)	
<b>Race, n (%)</b>				<b>p = 0.42</b>
Asian (1)	4 (1.3)	2 (1.3)	2 (1.3)	
Black or African American (2)	5 (1.7)	4 (2.6)	1 (0.7)	
Mexican American Indian (3)	1 (0.3)	1 (0.7)	0 (0.0)	
White or Caucasian (1)	291 (96.7)	144 (95.4)	147 (98.0)	
<b>Ethnicity, n (%)</b>				<b>p &lt; 0.001</b>
Hispanic or Latino (1)	28 (9.3)	25 (16.6)	3 (2.0)	
Not Hispanic or Latino (2)	271 (90.0)	124 (82.1)	147 (98.0)	
Refused to Report (9)	2 (0.7)	2 (1.3)	0 (0.0)	
<b>Race + Ethnicity, n (%)</b>				<b>p &lt; 0.001</b>
Asian (1)	2 (0.7)	0 (0.0)	2 (1.3)	
Hispanic (2)	25 (8.3)	22 (14.6)	3 (2.0)	
Mixed Race/Ethnicity (3)	3 (1.0)	3 (2.0)	0 (0.0)	
Non-Hispanic Black (4)	5 (1.7)	4 (2.6)	1 (0.7)	
Non-Hispanic White (5)	266 (88.4)	122 (80.8)	144 (96.0)	

**Table 2: Patient comorbidity details.**

<b>Comorbidity Measure</b>	<b>Comorbidity Group (n = 151)</b>
<b>Diabetes, n (%)</b>	
No (0)	110 (72.8)
Yes (1)	41 (27.2)
<b>Diabetic Category, n (%)</b>	n = 41
HbA1C < 6.5 (1)	14 (34.1)
HbA1C < 7 (2)	8 (19.5)
HbA1C = 7.1 - 8.0 (3)	4 (9.8)
HbA1C = 8.1 - 9.0 (4)	6 (14.6)
HbA1C > 9.0 (5)	6 (14.6)
Unknown (Blank)	3 (7.3)
<b>History of Hypertension, n (%)</b>	
No (0)	81 (53.6)
Yes (1)	70 (46.4)
<b>Hypertension Category at Visit, n (%)</b>	
Normal: < 120 (0)	32 (21.2)
Elevated: 120-129 (1)	11 (7.3)
HTN Stage 1: 130-139/80-89 (2)	44 (29.1)
HTN Stage 2: 140+/90+ (3)	64 (42.4)
<b>ACE-I or ARB at Visit, n (%)</b>	
No	100 (66.2)
Yes:	
ACE-I	24 (15.9)
ARB	9 (6.0)
ARB & ACE-I	5 (3.3)
Unknown	13 (8.6)
<b>Obesity, n (%)</b>	
No (0)	36 (23.8)
Yes (1)	115 (76.2)
<b>Obesity Category, n (%)</b>	n = 115
BMI = 30.0 - 34.9 (1)	66 (57.4)
BMI = 35.0 - 39.9 (2)	34 (29.6)

BMI = 40.0+ (3)	15 (13.0)
<b>Current Smoker, n (%)</b>	
No (0)	142 (94.0)
Yes (1)	9 (6.0)
<b>Asthma, n (%)</b>	
No (0)	140 (92.7)
Yes (1)	11 (7.3)
<b>COPD, n (%)</b>	
No (0)	150 (99.3)
Yes (1)	1 (0.7)
<b>Use of Inhaler for Asthma/COPD, n (%)</b>	
No (0)	142 (94)
Yes (1)	7 (4.6)
Unknown	2 (1.3)
<b>History of Blood Clots, n (%)</b>	
No (0)	151 (100.0)
Yes (1)	0 (0.0)
<b>Total Number of Comorbidities</b>	
Mean (SD)	1.6 (0.7)
Median [Q1, Q3]	2 [1, 2]

**Table 3: Patient COVID-19 characteristics and outcomes overall and by group.**

<b>Study Measure or Outcome</b>	<b>Total Study Sample (n = 301)</b>	<b>Group 1: Comorbidities (n = 151)</b>	<b>Group 2: Controls (n = 150)</b>	<b>P-Value</b>
<b>COVID Related Measures</b>				
<b>Symptomatic, n (%)</b>				p = 0.61
No (0)	37 (12.3)	20 (13.2)	17 (11.3)	
Yes (1)	264 (87.7)	131 (86.8)	133 (88.7)	
<b>Cough/Shortness of Breath, n (%)</b>				p = 0.09
No (0)	160 (53.2)	73 (48.3)	87 (58.0)	
Yes (1)	141 (46.8)	78 (51.7)	63 (42.0)	
<b>Shortness of Breath, n (%)</b>				p = 0.046
No (0)	241 (80.1)	114 (75.5)	127 (84.7)	
Yes (1)	60 (19.9)	37 (24.5)	23 (15.3)	
<b>Diarrhea, n (%)</b>				p = 0.01
No (0)	288 (95.7)	140 (92.7)	148 (98.7)	
Yes (1)	13 (4.3)	11 (7.3)	2 (1.3)	
<b>Weakness/Fatigue, n (%)</b>				p = 0.003
No (0)	142 (47.2)	84 (55.6)	58 (38.7)	
Yes (1)	159 (52.8)	67 (44.4)	92 (61.3)	
<b>Fatigue, n (%)</b>				p = 0.44
No (0)	203 (67.4)	105 (69.5)	98 (65.3)	
Yes (1)	98 (32.6)	46 (30.5)	52 (34.7)	
<b>Fever, n (%)</b>				p = 0.60
No (0)	137 (45.5)	71 (47.0)	66 (44.0)	
Yes (1)	164 (54.5)	80 (53.0)	84 (56.0)	
<b>Loss of Smell, n (%)</b>				p = 0.03
No (0)	193 (64.1)	106 (70.2)	87 (58.0)	
Yes (1)	108 (35.9)	45 (29.8)	63 (42.0)	
<b>Cardiopulmonary Symptom(s), n (%)</b>				p = 0.09
No (0)	154 (51.2)	70 (46.4)	84 (56.0)	

Yes (1)	147 (48.8)	81 (53.6)	66 (44.0)	
<b>GI Symptom(s), n (%)</b>				p < 0.001
No (0)	269 (89.4)	122 (80.8)	147 (98.0)	
Yes (1)	32 (10.6)	29 (19.2)	3 (2.0)	
<b>Constitutional Symptom(s), n (%)</b>				p = 0.06
No (0)	112 (37.2)	64 (42.4)	48 (32.0)	
Yes (1)	189 (62.8)	87 (57.6)	102 (68.0)	
<b>Musculoskeletal Symptom(s), n (%)</b>				p = 0.63
No (0)	248 (82.4)	126 (83.4)	122 (81.3)	
Yes (1)	53 (17.6)	25 (16.6)	28 (18.7)	
<b>Vision Symptom(s), n (%)</b>				p = 0.37
No (0)	297 (98.7)	148 (98.0)	149 (99.3)	
Yes (1)	4 (1.3)	3 (2.0)	1 (0.7)	
<b>Brain Fog/Confusion Symptom(s), n (%)</b>				p = 1.0
No (0)	298 (99.0)	149 (98.7)	149 (99.3)	
Yes (1)	3 (1.0)	2 (1.3)	1 (0.7)	
<b>"Other" Symptom(s), n (%)</b>				p = 0.02
No (0)	184 (61.1)	82 (54.3)	102 (68.0)	
Yes (1)	117 (38.9)	69 (45.7)	48 (32.0)	
<b>Total Number of Symptoms</b>				p = 0.58
Range	0 - 9	0 - 9	0 - 6	
Mean (SD)	2.6 (1.7)	2.7 (1.9)	2.5 (1.5)	
Median [Q1, Q3]	3 [1, 4]	3 [1, 4]	3 [2, 4]	
<b>Patient Care &amp; Outcome Measures</b>				
<b>Sent Home from Doctor on O2, n (%)</b>				p = 1.0
No (0)	295 (98.0)	148 (98.0)	147 (98.0)	
Yes (1)	6 (2.0)	3 (2.0)	3 (2.0)	
<b>Admitted to Hospital, n (%)</b>				p = 0.002
No (0)	273 (90.7)	129 (85.4)	144 (96.0)	
Yes (1)	28 (9.3)	22 (14.6)	6 (4.0)	

<b>Sent to ICU, n (%)</b>				p = 0.02
No (0)	291 (96.7)	142 (94.0)	149 (99.3)	
Yes (1)	10 (3.3)	9 (6.0)	1 (0.7)	
<b>Ventilation Needed, n (%)</b>				p = 0.21
No (0)	295 (98.0)	146 (96.7)	149 (99.3)	
Yes (1)	6 (2.0)	5 (3.3)	1 (0.7)	
<b>Sent Home from Hospital on O2, n (%)</b>				p = 0.72
No (0)	293 (97.3)	146 (96.7)	147 (98.0)	
Yes (1)	8 (2.7)	5 (3.3)	3 (2.0)	
<b>Severity of Case (4-level), n (%)</b>				p = 0.18
Asymptomatic infection (1)	35 (11.6)	20 (13.2)	15 (10.0)	
Symptomatic but not requiring anything (2)	234 (77.8)	107 (70.9)	127 (84.7)	
Symptomatic but requiring home oxygen (3)	4 (1.3)	2 (1.3)	2 (1.3)	
Symptomatic requiring hospitalization (4)	28 (9.3)	22 (14.6)	6 (4.0)	

**Table 4A: Penalized Multivariable Binary Regression Model Results with binary comorbidity categories.**

	$\beta$ coef.	SE	P Value		AOR	95% CI LB	95% CI UB
INTERCEPT	-2.726	1.961	0.047		-	-	-
AGE GROUP = 65+	2.080	0.471	< 0.001		8.007	3.249	20.722
GENDER = MALE	1.117	0.497	0.016		3.055	1.217	8.672
RACE/ETHNICITY = HISPANIC	-0.878	2.031	0.631		0.415	0.023	64.881
RACE/ETHNICITY = MIXED RACE	-1.320	2.617	0.559		0.267	0.001	61.757
RACE/ETHNICITY = NON-HISPANIC BLACK	0.747	2.298	0.699		2.111	0.052	414.054
RACE/ETHNICITY = NON-HISPANIC WHITE	-1.769	1.948	0.358		0.170	0.012	24.652
DIABETES = YES	0.380	0.525	0.469		1.462	0.508	3.961
OBESITY = YES	1.296	0.464	0.004		3.655	1.500	9.517
HISTORY OF HYPERTENSION = YES	0.553	0.443	0.212		1.738	0.726	4.121
CURRENT SMOKER = YES	-0.280	1.042	0.780		0.756	0.061	4.357
ASTHMA = YES	1.182	0.784	0.135		3.262	0.667	13.479
COPD = YES	3.397	2.393	0.138		29.878	0.186	725.447

**Table 4B: Penalized Multivariable Binary Regression Model Results with detailed comorbidity categories.**

	$\beta$ coef.	SE	P Value		AOR	95% CI LB	95% CI UB
INTERCEPT	-2.772	1.967	0.045		-	-	-
AGE GROUP = 65+	2.236	0.516	0.000		9.351	3.438	27.370
GENDER = MALE	1.162	0.518	0.018		3.197	1.209	9.780
RACE/ETHNICITY = HISPANIC	0.060	2.056	0.972		1.062	0.053	170.106
RACE/ETHNICITY = MIXED RACE	-2.659	2.790	0.281		0.070	0.000	18.420
RACE/ETHNICITY = NON-HISPANIC BLACK	0.853	2.308	0.660		2.347	0.058	468.343
RACE/ETHNICITY = NON-HISPANIC WHITE	-1.687	1.951	0.377		0.185	0.013	26.871
DIABETIC.CATEGORY = HBA1C < 7.0	1.389	0.903	0.124		4.009	0.656	20.517
DIABETIC.CATEGORY = HBA1C: 7.1 - 8.0	2.738	1.462	0.062		15.459	0.845	244.781
DIABETIC.CATEGORY = HBA1C: 8.1 - 9.0	0.201	1.242	0.868		1.223	0.100	11.625
DIABETIC.CATEGORY = HBA1C > 9.0	-0.754	1.803	0.639		0.470	0.003	7.939
HYPERTENSION.CATEGORY = ELEVATED	0.513	0.937	0.587		1.670	0.238	9.590



HYPERTENSION.CATEGORY = HTN STAGE 1	0.437	0.651	0.504		1.548	0.426	5.631
HYPERTENSION.CATEGORY = HTN STAGE 2	-1.011	0.648	0.118		0.364	0.094	1.285
OBESITY.CATEGORY = BMI: 30.0 – 34.9	1.262	0.633	0.050		3.533	0.998	12.641
OBESITY.CATEGORY = BMI: 35.0 – 39.9	1.647	0.749	0.033		5.189	1.147	23.908
OBESITY.CATEGORY = BMI: 40.0+	2.631	0.922	0.007		13.889	2.113	87.043

Coef. = coefficient estimate; SE = Standard Error;

AOR = Adjusted Odds Ratio; CI = Confidence Interval; LB = Lower Bound; UB = Upper Bound

### Supplemental Table 1: Percentage of Patients with COVID-19 Severity Outcome as a Function of Single and Combination of Underlying Comorbid Conditions

Comorbidity Combination, n (Row %)	COVID-19 Severity		Total
	Mild (1)	Severe (2)	
0 - NONE	147 (94.8)	8 (5.2)	155
1 - DIABETES	5 (83.3)	1 (16.7)	6
1 - HISTORY OF HYPERTENSION	15 (88.2)	2 (11.8)	17
1 - OBESITY	51 (91.1)	5 (8.9)	56
2 - DIABETES + HISTORY OF HYPERTENSION	7 (87.5)	1 (12.5)	8
2 - DIABETES + OBESITY	12 (85.7)	2 (14.3)	14
2 - HISTORY OF HYPERTENSION + OBESITY	23 (71.9)	9 (28.1)	32
3 - DIABETES + HISTORY OF HYPERTENSION + OBESITY	9 (69.2)	4 (30.8)	13
Total	269	32	301

### Supplemental Figure 1: Script for Patient Follow-Up

Hello, May I please speak with [Insert Participant Name],

This is [Insert Researcher Name] calling on behalf of CHEMED Health Center. I am updating your patient chart and calling as a follow up, regarding your recent positive COVID-19 test.

I am going to list a few conditions and please let me know if you have been previously diagnosed with any of the following:

1. Diabetes
2. Hypertension (High Blood Pressure)
3. Current or Prior Smoker
4. Asthma

Next, I have a few questions regarding the severity of your condition when you contracted COVID-19.

1. What were your symptoms of COVID-19 (fever, cough, shortness of breath, diarrhea, weakness, fatigue, loss of smell)?
2. Were you sent home from the doctor's office on oxygen?
3. Were you hospitalized?
  - a. If yes: were you in the ICU?
    - i. If yes: were you placed on a ventilator and/or were you sent home from the hospital on oxygen